Key clinical point: GAG measurements can provide accurate diagnostic and prognostic information for surgically treated renal cell carcinoma.
Major finding: A new GAG score had 93.5% sensitivity and 94.7% specificity for differentiating RCC from controls.
Study details: Retrospective case-control study that included 175 RCC patients and 19 controls.
Disclosures: The study was funded by the Knut and Alice Wallenberg Foundation to Chalmers University of Technology and MSK Cancer Center Support Grant P30-CA008748 to the Memorial Sloan Kettering Cancer Center. Dr. Francesco Gatto and Dr. Jens Nielsen were listed as coinventors on patent applications related to the biomarkers described in this study and both are shareholders in Elypta AB, which owned the above-mentioned patent applications. There are no other disclosures.
Gatto F et al. Eur Urol Oncol. 2018 Jun 13. doi: 10.1016/j.euo.2018.04.015
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010
RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021